Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma
Sylvain SimonImmunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WashingtonStanley R. RiddellImmunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, Washington. [email protected]
2020en
ABI
Abstract
Summary: Adoptive T-cell therapy targeting a single tumor antigen can induce remissions of hematologic cancers but relapses often occur due to the outgrowth of tumor cells with absent or low expression of the antigen. Strategies to simultaneousy target multiple antigens are needed to fully capitalize on the promise of this therapeutic strategy. In this issue of Blood Cancer Discovery, Fernández de Larrea and colleagues demonstrate in preclinical models of multiple myeloma that targeting BCMA and GPRC5D simultaneously with T cells engineered to express chimeric antigen receptors specific for these antigens may prevent tumor cell escape. See related article by Fernández de Larrea et al., p. 146.
Identifiers
Citations and references
Cited by 30 references